XOMA Corp  

(Public, NASDAQ:XOMA)   Watch this stock  
Find more results for XOMA
3.36
-0.06 (-1.61%)
After Hours: 3.37 +0.01 (0.30%)
May 26, 6:48PM EDT  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 3.31 - 3.40
52 week 2.92 - 5.95
Open 3.39
Vol / Avg. 0.00/2.01M
Mkt cap 405.95M
P/E     -
Div/yield     -
EPS -0.50
Shares 117.82M
Beta 3.00
Inst. own 67%
Aug 5, 2015
Q2 2015 XOMA Corp Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
May 21, 2015
XOMA Corp Annual Shareholders Meeting
May 7, 2015
Q1 2015 XOMA Corp Earnings Call - Webcast
May 7, 2015
Q1 2015 XOMA Corp Earnings Release
May 6, 2015
XOMA Corp at Credit Suisse Antibody Day
Mar 11, 2015
Q4 2014 XOMA Corp Earnings Call - Webcast
Mar 11, 2015
Q4 2014 XOMA Corp Earnings Release
Mar 9, 2015
XOMA Corp at ROTH Conference
Mar 4, 2015
XOMA Corp at Cowen Health Care Conference
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '15) 2014
Net profit margin -819.24% -203.02%
Operating margin -851.49% -433.75%
EBITD margin - -423.24%
Return on average assets -103.89% -34.13%
Return on average equity - -
Employees 183 -
CDP Score - -

Address

2910 7th St
BERKELEY, CA 94710-2700
United States - Map
+1-510-6441170 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

XOMA Corporation (XOMA) is engaged in the discovery and development of antibody-based therapeutics. The Company’s lead product candidate, gevokizumab, is a proprietary potent, fully humanized allosteric-modulating monoclonal antibody that binds to the inflammatory cytokine interleukin-1 beta. The Company initiated three Phase III clinical trials evaluating gevokizumab for the treatment of non-infectious intermediate, posterior or pan-uveitis. It is also are conducting a trial of gevokizumab in pyoderma gangrenosum (PG), a rare ulcerative skin disease. It also has an active gevokizumab Proof-of-Concept (POC) development program to identify indications for pivotal development. XOMA 3AB is a multi-antibody product designed to neutralize the most potent of the botulinum toxins, Type A, which causes paralysis and is a bioterrorism threat.

Officers and directors

W. Denman Van Ness Lead Independent Chairman of the Board
Age: 72
Bio & Compensation  - Reuters
John W. Varian Chief Executive Officer, Director
Age: 55
Bio & Compensation  - Reuters
Thomas M. Burns Chief Financial Officer
Bio & Compensation  - Reuters
Patrick J. Scannon M.D., Ph.D. Executive Vice President, Chief Scientific Officer, Director
Age: 67
Bio & Compensation  - Reuters
Paul D. Rubin M.D. Senior Vice President - Research and Development, Chief Medical Officer
Age: 61
Bio & Compensation  - Reuters
Tom Klein Vice President, Chief Commercial Officer
Age: 53
Bio & Compensation  - Reuters
William K. Bowes Jr. Independent Director
Age: 88
Bio & Compensation  - Reuters
Peter Barton Hutt Independent Director
Age: 80
Bio & Compensation  - Reuters
Joseph M. Limber Independent Director
Age: 62
Bio & Compensation  - Reuters
Timothy P. Walbert Independent Director
Age: 48
Bio & Compensation  - Reuters